IPO Lisboa
Lisbon, Portugal
3 recruiting
Showing 1–5 of 5 trials
Recruiting
Phase 2Phase 3
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Advanced Melanoma
Eikon Therapeutics740 enrolled107 locationsNCT06697301
Recruiting
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
HER2-positive Advanced Gastric CancerHER2-positive Gastroesophageal Junction Adenocarcinoma
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company257 enrolled76 locationsNCT05993234
Recruiting
DESTINY Breast Respond HER2-low Europe
Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1,155 enrolled211 locationsNCT05945732
Recruiting
Phase 3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Cancer
Bayer402 enrolled383 locationsNCT04464226
Recruiting
Not Applicable
REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs
Anthracycline-induced Cardiac ToxicityLymphoma
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III608 enrolled24 locationsNCT05223413